Navigation Links
Bayer and Onyx Announce Nexavar Data Presentations at 60th American Association for the Study of Liver Diseases Annual Meeting
Date:10/29/2009

WAYNE, N.J. and EMERYVILLE, Calif., Oct. 29 /PRNewswire-FirstCall/ -- Bayer HealthCare Pharmaceuticals, Inc. and Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that more than 25 studies evaluating the use of Nexavar® (sorafenib) tablets in liver cancer will be presented at The Liver Meeting®, the 60th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD). Nexavar is the only systemic treatment to demonstrate prolonged survival in patients with hepatocellular carcinoma (HCC), the most common form of liver cancer, and is currently approved in more than 80 countries for the treatment of the disease.

"Bayer and Onyx are committed to further evaluating Nexavar in patients with HCC to find the safest and most effective treatment regimens to help liver cancer patients better manage their disease," said Mark Gelder, vice president, Bayer Global Medical Affairs, Oncology. "While we are encouraged by the role Nexavar has played in treating these patients, we continue to evaluate Nexavar in a variety of treatment settings, including in combination with TACE and other systemic therapies, and as a monotherapy in the adjuvant setting."

Nexavar data highlights include:

Phase II Trial of Sorafenib Combined with Doxorubicin Eluting Bead-Transarterial Chemoembolization (DEB-TACE) for Patients with Hepatocellular Carcinoma (HCC): Interim Safety and Efficacy Analysis

  • Jean-Francois Henri Geschwind, The Johns Hopkins University School of Medicine, Baltimore, MD
  • Monday, November 2, 2009, 8:00 a.m. - 8:00 p.m., Exhibit Hall C
  • Late Breaker #9

First-in-men Demonstration of Sorafenib Plus TACE for the Treatment of Advanced Hepatocellular Carcinoma (SOCRATES trial)

  • Dr. Andreas Erhardt, Klinik fur
    '/>"/>

SOURCE Onyx Pharmaceuticals, Inc.; Bayer HealthCare Pharmaceuticals Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Bayers Novel Anti-Cancer Compound Regorafenib (BAY 73-4506) Showed Stabilization or Regression in 81 Percent of Kidney Cancer Patients
2. Bayer Announces New Data on Oncology Portfolio To Be Presented at the ECCO-ESMO Congress 2009
3. Enrollment Completed in Regeneron and Bayer HealthCare Phase 3 Studies of VEGF Trap-Eye in Neovascular Age-Related Macular Degeneration (Wet AMD)
4. Bayer Announces New Data on Novel Anti-cancer Compound BAY 73-4506
5. Bayer Announces Leukine(R) Data Presentations at 45th American Society of Clinical Oncology (ASCO) Annual Meeting
6. Bayer and Regeneron Extend Development Program for VEGF Trap-Eye to Include Central Retinal Vein Occlusion
7. Bayer Announces Upcoming Presentations of Campath(R) and Leukine(R) Data at the 50th Annual Meeting of the American Society of Hematology
8. FDA Approves Bayer HealthCares Kogenate(R) FS Treatment for Routine Prophylaxis in Children with Hemophilia A
9. Bayer and Onyx Begin Enrollment in STORM Trial Studying Nexavar as Adjuvant Therapy for Patients With Liver Cancer
10. Cell Therapeutics, Inc. (CTI) to Hold Conference Call to Discuss Agreement With Bayer Schering Pharma for Access to Phase III Zevalin(R) FIT Trial Data
11. Bayer HealthCare Celebrates 20th Anniversary of Kogenate(R) Product Line and 8 Billion IU Milestone at 2008 WFH World Congress
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... 30, 2014   ViaDerma, Inc. (OTCQB: ... new products to market, has recently released a ... is a topical liquid tetracycline-based antibiotic that uses ... convert oral medication active ingredients into topical drugs. ... aid antibiotic to help prevent skin infection in ...
(Date:10/30/2014)... 30, 2014 CVS Health (NYSE: CVS ... with three leading regional health systems to enhance access to ... systems include Baptist Health System in Alabama ... Health in Pennsylvania , Northwest Medical Center, ... and Tennova Healthcare in Tennessee ; and ...
(Date:10/30/2014)... 30, 2014 Molecular Profiles Ltd., a subsidiary ... and Maryland -based Xceleron have announced ... during clinical development that will be launched at AAPS ... This partnership extends Molecular Profiles, new ROADMAP ... earlier this month. The company also has complementary collaborations ...
Breaking Medicine Technology:ViaDerma, Inc. Lead Product TetraStem Shown Effective in Fighting Staph Infections including MRSA 2ViaDerma, Inc. Lead Product TetraStem Shown Effective in Fighting Staph Infections including MRSA 3CVS Health Announces New Clinical Affiliations with Leading Regional Health Systems 2CVS Health Announces New Clinical Affiliations with Leading Regional Health Systems 3CVS Health Announces New Clinical Affiliations with Leading Regional Health Systems 4Molecular Profiles To Launch US Strategic Alliance At AAPS 2Molecular Profiles To Launch US Strategic Alliance At AAPS 3
... Nordisk Inc., a global healthcare company and leader in diabetes care, today ... information on diabetes and chronic disease, highlighting key issues in diabetes prevention, ... , ... evolved over the last 90 years, how it is developed today, the ...
... NEW ORLEANS , July 12 Proventix Systems, Inc., of ... Alabama -based technology company, that will help them fight the spread ... , , , , ... in Infection Control and Epidemiology, HAIs contribute $28 billion to $33 ...
Cached Medicine Technology:Novo Nordisk Addresses Innovation in Diabetes Care in Second Issue of Industry Resource for Information on Diabetes and Chronic Disease 2Proventix™ Partners with Synapse Wireless to Save Lives 2Proventix™ Partners with Synapse Wireless to Save Lives 3
(Date:10/30/2014)... Five months after their expansion, the ... new branding and a website to accompany their recent ... Mepham’s promotion to name partner earlier this year, Hodgkinson ... Mepham’s name and better reflect their combined litigation expertise. ... decision to implement new branding reflects Hodgkinson Street Mepham’s ...
(Date:10/30/2014)... CT (PRWEB) October 30, 2014 Radio ... are raising questions about the impact of traditional radio ... marketing method most likely to influence a purchasing decision. ... poll of 525 consumers conducted by radio marketing company ... product categories, isolating the results of respondents who indicated ...
(Date:10/30/2014)... Dennis Thompson HealthDay ... The Ebola outbreak in Liberia -- one of three West ... World Health Organization officials said Wednesday. Dr. Bruce Aylward, ... the number of burials in Liberia and no increase in ... global push to tame the epidemic may be making some ...
(Date:10/30/2014)... 30, 2014 Horse Sense & ... riding to special needs individuals in the Jacksonville area, ... November 15 from 10-2:00 p.m. at Bailey's Farm (2202 ... to the public and is designed to raise awareness ... to the HSS Round-Up is free. Ticket purchases will ...
(Date:10/30/2014)... (PRWEB) October 30, 2014 REV'D Provision ... are now available through a unique service called, ... designed to empower the everyday athlete. The Feed has ... athletes and created a system to pass that information ... see REV’D® is now available on The Feed!” says ...
Breaking Medicine News(10 mins):Health News:Hodgkinson Street Mepham Rebrands 2Health News:CRN Research On Radio Messaging Effectiveness Now Available In Four Specific Product Categories 2Health News:CRN Research On Radio Messaging Effectiveness Now Available In Four Specific Product Categories 3Health News:Ebola Outbreak in Liberia May Be Slowing: WHO 2Health News:Ebola Outbreak in Liberia May Be Slowing: WHO 3Health News:Horse Sense & Sensitivity, Jacksonville Non-profit, To Hold 2nd Annual Round-Up 2Health News:Nutrition Experts at TheFeed.com Get REV'D 2Health News:Nutrition Experts at TheFeed.com Get REV'D 3
... MONICA, Calif., Feb. 3 The most common New ... on,physical appearance: lose weight, tone up, exercise more, and ... finding an intimate relationship,between body and mind. In order ... to maintain mental health and cognitive function as well ...
... 3 The US market for the drug treatment of ... to US Cancer Pain, a report released today by WWMR, ... a trend expected to continue throughout the next decade. ... primary driver of market value during the forecast period. ...
... CDC reports decline in two-thirds of the country, , , TUESDAY, ... decade in nearly two-thirds of the states, according to a ... Prevention. , The CDC,s data analysis showed that mammography use ... including Minnesota, Tennessee, Georgia and Alabama. But it fell by ...
... play a critical role in world,s largest global ... coming months, hundreds of Rotary club members from ... the United Kingdom and the Caribbean will join ... and health workers to immunize children against polio ...
... Breakthrough findings contribute to better understanding of little-known disease ... Feb. 3 A new research study has identified ... primary torsion dystonia (DYT6 type) in Amish-Mennonite families and ... that THAP1 causes dystonia in other ethnic groups.A paper ...
... Texas, Feb. 3 UpSpring Baby (TM) today ... breast milk is now available for purchase over-the-counter at ... is the nation,s largest drugstore chain and the first ... test. Milkscreen is also available for purchase through ...
Cached Medicine News:Health News:Dakim Recommends Six New Year Resolutions to Stay Cognitively Fit 2Health News:US Cancer Pain Market to Reach $5 Billion by 2018 - Cancer Patient Growth Drives Value 2Health News:US Cancer Pain Market to Reach $5 Billion by 2018 - Cancer Patient Growth Drives Value 3Health News:Fewer Women Are Having Mammograms 2Health News:Rotary Members Worldwide Prepare For Mass Immunization Campaigns In Polio-Endemic Countries 2Health News:Rotary Members Worldwide Prepare For Mass Immunization Campaigns In Polio-Endemic Countries 3Health News:The Bachmann-Strauss Dystonia & Parkinson Foundation: New Study Identifies Gene Mutations as Cause of Dystonia in Amish-Mennonite Families 2Health News:Milkscreen Home Test for Alcohol in Breast Milk Begins Nationwide Sales at Walgreens 2
... Dynal RELI™ SSO typing technique utilises a ... flank the specific target region of an ... of the resulting amplicon to an array ... a nylon membrane. The immobilisation of these ...
... The Reichert UNISTAT ... photometric analyzer for determining ... newborn infants. It quickly ... tests are needed by ...
Biotest ELPHA (=Enzyme Linked Probe Hybridization Assay) for class I and class II HLA typing shows convincing advantages for your lab routine....
... Follicle-Stimulating Hormone (FSH) is a glygoprotein produced by ... as LH, TSH, and HCG, FSH consists of ... is a solid phase direct sandwich ELISA method. ... to the wells coated with Mab to FSH ...
Medicine Products: